🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

RLMD RLMD

Company Profile ↓
$5.44
+784.55% 1Y
Mkt Cap$398.93M
P/E-3.75
P/B4.61
52W High$7.86
52W Low$0.56
Book Value$1.18
EPS (TTM)$-1.45

Company Overview

RLMD (RLMD) is a publicly traded company listed on with a market capitalization of $398.93M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Growth & Price Performance

Stock Price Performance

1 Year:+784.55%
6 Months:+43.16%
3 Months:-25.99%
1 Month:-15.13%
Technical Snapshot Mixed
52-Week Range 67% of range
$0.56 $7.86
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)43.33 · Neutral
Price Performance
1M-15.13%
3M-25.99%
6M+43.16%
1Y+784.55%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 30.8% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.75
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$1.18
Price to Book
4.61
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-67.49%
ROE
-66.33%
ROA
-61.05%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.22
EPS (TTM)
$-1.45

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
14.62
Debt
-
Total Assets
$235.36M
Current Assets
$235.34M
Working Capital
$87.55M

Ownership

Promoter Holding
2.90%
Chg in Prom Hold
0.00%
FII / Inst Holding
85.09%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-59.10M
Free Cash Flow
$-45.79M
Operating Cash Flow
$-45.79M
Shares Outstanding
73.33M
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2013Feb 2014Mar 2014Sep 2014Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Sep 2017Dec 2017Mar 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -682---------------------------------00000
Cost of Revenue ----------------------------------------
Gross Profit --3--------------------------------------
Operating Expenses -----------------------------------18.22M10.22M10.33M20.33M19.46M
Operating Income -5.06M-3.12K-711.90K-3.72M-4.38M-4.58M-4.63M-5.72M-2.75M-1.62M-1.54M-2.28M-980.86K-1.46M-2.55M-2.41M-3.48M-2.70M-4.14M-3.71M-9.97M-12.76M-17.18M-22.41M-26.46M-42.65M-38.30M-45.51M-38.74M-28.15M-26.03M-22.69M-22.99M-18.82M-23.01M-18.22M-10.22M-10.33M-20.33M-19.46M
EBITDA ------------------------------------18.22M-10.22M-10.33M-20.33M-19.46M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------17.56M-9.87M-10.09M-19.87M-19.05M
Tax Provision ----------------------------------------
Net Income -5.17M-6.49M-29.84M5.46M-2.46M4.66M-2.46M-1.86M-1.64M-1.03M-1.98M-981.69K-1.43M-3.20M-3.38M-7.13M-2.69M-4.12M-3.67M-10.67M-11.12M-16.90M-22.22M-26.55M-42.61M-39.75M-39.93M-39.42M-26.32M-25.30M-22.00M-21.83M-17.77M-21.73M-17.56M-9.87M-10.09M-19.87M-19.05M
Diluted EPS -2.10-0.42-3.660.40-0.230.36-0.22-0.15-0.14-0.09-0.16--0.11---0.28--------1.56-2.44--1.33-1.31-0.87-0.84-0.73-0.72-0.59-0.72-0.58-0.30-0.30--0.22
R&D Expense -4.27M--215.79K718.97K2.09M2.27M2.87M2.12M609.12K364.15K254.10K490.69K165.75K150.72K1.67M1.42M1.26M1.28M3.07M1.89M4.51M5.32M11.24M14.02M17.33M33.99M25.01M30.91M30.53M15.86M13.74M10.45M13.31M10.72M11.15M11.95M2.82M4.04M-8.09M

Profit & Loss (Annual)

Figures in USD.

Metric Aug 2012Aug 2013Dec 2013Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 7.94K5.13K---------0000
Cost of Revenue ---------------
Gross Profit 2.14K1.09K-------------
Operating Expenses -----------161.25M103.70M83.89M59.10M
Operating Income -12.05K-45.02K-6.77M-17.10M-16.22M-7.22M-6.92M-12.73M-15.11M-60.84M--161.25M-103.70M-83.89M-59.10M
EBITDA ------------161.25M-103.70M-83.89M-59.10M
Interest Expense ---------------
Pretax Income ------------157.04M-98.79M-79.98M-57.39M
Tax Provision ---------------
Net Income -12.05K-45.02K-19.87M-20.80M-2.97M-6.29M-8.96M-17.32M-15.01M-59.46M--157.04M-98.79M-79.98M-57.39M
Diluted EPS ------------5.30-3.28-2.65-1.45
R&D Expense --5.25M7.87M6.21M1.29M2.94M7.02M7.86M35.97M90.62M113.32M54.81M46.18M26.88M

Balance Sheet (Annual)

Figures in USD.

Metric Aug 2011Aug 2012Dec 2012Aug 2013Dec 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Dec 2018Jun 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -18.35K-20.01K-25.76M24.39M10.24M2.84M3.05M-10.22M117.14M118.19M-152.91M97.55M45.82M94.00M
Current Assets ---------------152.87M97.51M45.80M93.98M
Cash & Equivalents --1.77M-3.52M25.56M22.47M8.50M1.71M2.24M2.43M9.22M36.28M2.50M-5.40M4.09M3.86M3.50M
Inventory -------------------
Receivables --------------86.38K512.43K0--
Total Liabilities -----26.87M15.58M3.20M1.38M8.56M-2.61M1.46M12.60M-12.47M12.19M10.30M7.49M
Current Liabilities -7.00K-33.67K-26.77M15.58M3.06M1.38M5.90M-2.61M1.46M12.60M-12.47M12.19M10.29M6.43M
Long Term Debt -------------------
Total Debt -------------------
Total Equity 9.91K11.36K-3.71M-13.66K-17.95M-1.11M8.81M7.04M1.46M-5.51M-7.61M115.68M105.58M-140.44M85.36M35.52M86.51M
Shares Outstanding ---------------30.10M30.10M30.17M73.33M

Cash Flows (Annual)

Figures in USD.

Metric Aug 2012Aug 2013Dec 2013Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -7.57K-11.86K-2.24M-16.23M-13.14M-6.47M-6.00M-10.50M-12.09M-27.81M--103.80M-51.66M-51.76M-45.79M
Investing Cash Flow --1.80K-8.87K-23.33K-562.26K-49.69K-12.39K--80.16M-34.45M-19.73M50.45M51.56M-48.14M
Financing Cash Flow 13.50K20.00K4.00M13.16M-263.75K-273.67K6.54M17.48M126.11M28.47M-45.02M-98.46K-40.34K93.56M
Capital Expenditure -1.80K-------------
Free Cash Flow --10.06K----------103.80M-51.66M-51.76M-45.79M
Net Change in Cash ------------39.05M-1.30M-234.54K-360.49K

Ratios (Annual)

Figures in %.

Metric Aug 2012Aug 2013Dec 2013Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 27.0%21.3%-------------
Operating Margin % -151.8%-877.7%-------------
Net Margin % -151.8%-877.7%-------------
ROE % -106.1%329.6%110.7%-236.1%-42.2%-430.5%162.5%-227.5%-13.0%-56.3%--111.8%-115.7%-225.2%-66.3%
ROCE % -106.1%329.6%--194.1%-225.7%-494.3%242.2%-167.2%-13.1%-57.6%--114.8%-121.5%-236.1%-67.5%

Shareholding Pattern

Insiders
2.90%
Institutions
85.09%
Public Float
87.63%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RLMD

Google News hu, 16 Jul 2026

Relmada Sets Aug. 6 Call to Discuss Second-Quarter Results - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaXdNQ3BXYlgxV3k2dlR3bE44RGc0aXNhU2dmeVlXeFJmdE9Qb0NIVHF4ZFl5d0dHSHd4Qk5rXzJiMzcwNFB5MnFxTnhwS1g0MGs1cnhzdWx4RGhyc25XVEVzUEN2MXEwX3FSMWhnRmlYcWxSbm13d2tRV04tMFI4MjkwZU5BNEJ2ZU1DQ2…

Google News Fri, 19 Jun 2026

Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOc2lmUHFjQlhWTmVtRDZaVnJaVkViU2tzTEtPcmp5c1ZDdUJxTk8yOTZlZ0VPYUhPdTdqeVRkMFlBUndwQkhqczRzeGFYc2JaZXoyQ3pWUWF5Sm9RdTZwX0JTMWlzOWo2QmdWZ0cyckFsTGJZVVdHQzlhcWp0SmpXWW5qQ0o1UFY0UngtYm…

Google News Fri, 26 Jun 2026

RLMD Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9FLVBENVVfWVlqbkg4NVoyakdnS1RJcVlWdTgxQjJJM3Fvbm03NnluVlJEY2JwdFNmRThWclJvWU9KeUZjR20xNzVqUjVlN0ltTHhwV2NlQV9uck93TnUta1RUSHFIek5MR1A2LUV2MUNlTkxIa2tLSDh3?oc=5" target="_blank">RLM…

Google News Wed, 22 Apr 2026

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNYWdLdG5pQUtrQW1mUHF1ODRSWFJTS2JTOTNxU0NveGtvM2drazdxYTJHcDBoanVKUTlGeTRYOE5vTWFHUVBLSjVzWU5qWEx2a1R1Ykc1N2JNMVFJdEpjYkJtRklQLTlDUXVIejJCWDd3SldPWTgtcFpRbkdYUy13TkpDUi0wVDFIVXF4ZG…

Google News Mon, 09 Mar 2026

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - Stocktwits

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQbTN5NWg1U3NPN21OdFJZQW4yall2SXd5Zi1abmF2WWxFMWVQYjA1MFlFZDU3cGkzUnktc1gyQlM0S0RKYUp0LWZyb05Vd2R5dERsODktcF84aXhSMjFxemdjUlM0ejluRXV1dktTVHRYbUtpMVpEWFJta1BZcmhWOWZuTm9ZeTh3NHVfV2…

Google News Mon, 09 Mar 2026

Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal - Tokenist

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQdUpXSEFHdUt3YzhBM1JiTUUzb3lISjJfeXRHX2dFR1R5b1MzcE1MTG1iNk1KNlhiSzZGd2tDYXc3b0MtNnE0UEI0LXN2TTdRQ2o1S1VtNWlockpod2ZkbjJSUXB6UXpkTzNDVkhxNWNlUUpBaF96Y2FDUl81MXdBY0tUZEYzSzBIQlVIV0…

RLMD — Frequently Asked Questions

What is the current share price of RLMD?

As of 2026-08-05 17:25 PDT, RLMD trades at $5.44 on NASDAQ/NYSE. Its 52-week range is $0.56 to $7.86.

What is the market capitalisation of RLMD?

RLMD has a market capitalisation of $398.93M on NASDAQ/NYSE.

What is the P/E ratio of RLMD?

RLMD trades at a trailing price-to-earnings (P/E) ratio of -3.75. Its price-to-book (P/B) ratio is 4.61.

What is the return on equity (ROE) of RLMD?

RLMD has a return on equity (ROE) of -66.33%. Its return on capital employed (ROCE) is -67.49%.

Is RLMD a good stock to buy?

This page provides a data-driven analysis of RLMD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space